Danaher Provides Update On First Quarter 2021 Financial Performance
b'WASHINGTON, April 13, 2021 /PRNewswire/ --Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company\'s previously communicated guidance range.\nFor the quarter ended April 2, 2021, the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth including Cytiva to be approximately 29.0%.
- b'WASHINGTON, April 13, 2021 /PRNewswire/ --Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company\'s previously communicated guidance range.\nFor the quarter ended April 2, 2021, the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth including Cytiva to be approximately 29.0%.
- The better-than-expected performance was broad-based across the portfolio, with particular strength in Life Sciences and Diagnostics.\nAs previously announced, Danaher will hold its earnings conference call for the first quarter 2021 on Thursday, April 22, 2021 at 8:00 a.m. ET.\nDanaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world.
- Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets.
- For more information, please visit www.danaher.com .\nIn addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures.